The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: The Jackson Heart Study

Abstract

Background

Dyslipidemia plays a significant role in the progression of cardiovascular disease. The apolipoprotein (apo) A1 remnant ratio (apo A1/VLDL₃-C + IDL-C) has recently been shown to be a strong predictor of death/myocardial infarction risk among women >50 years undergoing angiography. However, whether this ratio is associated with coronary heart disease risk among other populations is unknown. We evaluated the apo A1 remnant ratio and its components for coronary heart disease incidence.

Design

Observational.

Methods

Participants (N = 4722) of the Jackson Heart Study were evaluated. Baseline clinical characteristics and lipoprotein subfractions (Vertical Auto Profile method) were collected. Cox hazard regression analysis, adjusted by standard cardiovascular risk factors, was utilized to determine associations of lipoproteins with coronary heart disease.

Results

Those with new-onset coronary heart disease were older, diabetic, smokers, had less education, used more lipid-lowering medication, and had a more atherogenic lipoprotein profile. After adjustment, the apo A1 remnant ratio (hazard ratio = 0.67 per 1-SD, p = 0.002) was strongly associated with coronary heart disease incidence. This association appears to be driven by the IDL-C denominator (hazard ratio = 1.23 per 1-SD, p = 0.007). Remnants (hazard ratio = 1.21 per 1-SD, p = 0.017), but not apo A1 (hazard ratio = 0.85 per 1-SD, p = 0.121) or VLDL₃-C (hazard ratio = 1.13 per 1-SD, p = 0.120) were associated with coronary heart disease. Standard lipids were not associated with coronary heart disease incidence.

Conclusion

We found the apo A1 remnant ratio to be strongly associated with coronary heart disease. This ratio appears to better stratify risk than standard lipids, apo A1, and remnants among a primary prevention cohort of African Americans. Its utility requires further study as a lipoprotein management target for risk reduction.

Keywords

Lipids lipoprotein subfractions lipoprotein ratios risk gender;outcomes apolipoproteins remnant lipoproteins

Get full access to this article

View all access options for this article.

References

Mozaffarian

Roger

. Heart disease and stroke statistics – 2013 update: A report from the American Heart Association. Circulation 2012; 127: e6–e245.

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.

May

Nelson

Kulkarni

. A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: The apolipoprotein A1 remnant ratio (Apo A1/[VLDL3 + IDL]). Lipids Health Dis 2013; 12: 55–55.

Taylor

Jr Wilson

Jones

. Toward resolution of cardiovascular health disparities in African Americans: Design and methods of the Jackson Heart Study. Ethn Dis 2005; 15: S6–4–17.

Sempos

Bild

Manolio

. Overview of the Jackson Heart Study: A study of cardiovascular diseases in African American men and women. Am J Med Sci 1999; 317: 142–146.

Wyatt

Diekelmann

Henderson

. A community-driven model of research participation: The Jackson Heart Study Participant Recruitment and Retention Study. Ethn Dis 2003; 13: 438–455.

Kulkarni

Garber

Marcovina

. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 1994; 35: 159–168.

Kulkarni

Tiwari

Jones

. A novel approach to measure apolipoprotein A/apolipoprotein A1 ratio using the Vertical Auto Profile method. Diab Vasc Dis Res 2007; 4: 266–266.

Keku

Rosamond

Taylor

Jr . Cardiovascular disease event classification in the Jackson Heart Study: Methods and procedures. Ethn Dis 2005; 15: S6–62–70.

10.

Pencina

D’Agostino

Zdrojewski

. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol, 22: 1321–1327. . DOI: 10.1177/2047487315569411. Epub ahead of print 29 January 2015.

11.

Thanassoulis

Williams

. Relations of change in plasma levels of LDL-C, Non-HDL-C, and apo B with risk reduction from statin therapy: A meta-analysis of randomized trials. J Am Heart Assoc 2014; 3: e000759–e000759.

12.

Sierra-Johnson

Fisher

Romero-Corral

. Concentration on apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-1 ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: Findings from a multi-ethnic US population. Eur Heart J 2009; 30: 710–717.

13.

Freedman

Strogatz

Eaker

. Differences between black and white men in correlates of high density lipoprotein cholesterol. Am J Epidemiol 1990; 132: 656–669.

14.

Haffner

D’Agostino

Jr Goff

. LDL size in African Americans, Hispanics, and non-Hispanic whites: The insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 1999; 19: 2234–2240.

15.

Manolio

Pearson

Wenger

. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol 1992; 2: 161–176.

16.

Lamarche

Moorjani

Lupien

. Apolipoprotein A-1 and B levels and risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996; 94: 273–278.

17.

Gofman

Lindgren

. The role of lipids and lipoproteins in atherosclerosis. Science 1950; 111: 166–171.

18.

Mack

Krauss

Hodis

. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996; 16: 697–704.

19.

Krauss

Lindgren

Williams

. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987; 2: 62–66.

20.

Varbo

Benn

Tybjaerg-Hansen

. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61: 427–436.

21.

Varbo

Benn

Smith

. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res 2015; 116: 665–673.

22.

Park

Lee

Kim

. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther 2005; 312: 1241–1248.

23.

Koga

Sugiyama

Kugiyama

. Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease. Eur Heart J 2006; 27: 817–823.

24.

Fibrinogen Studies

Collaboration

Danesh

Lewington

. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA 2005; 294: 1799–1809.

25.

Allison

Criqui

McClelland

. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006; 48: 1190–1197.

26.

Tracy

Bovill

Fried

. The distribution of coagulation factors VII and VIII and fibrinogen in adults over 65 years. Results from the Cardiovascular Health Study. Ann Epidemiol 1992; 2: 509–519.

27.

Varbo

Benn

Tybjaerg-Hansen

. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013; 128: 1298–1309.

28.

Ford

Ajani

Croft

. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 2007; 356: 2388–2398.

29.

Ford

Giles

Dietz

. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359.

30.

Bitner

Johnson

Zineh

. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: A Report From the Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J 2009; 157: 548–555.

31.

Frohlich

Dobiasova

. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003; 49: 1873–1880.

32.

Walldius

Jungner

Holme

. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial (AMORIS study): A prospective study. Lancet 2001; 358: 2026–2033.

33.

Benn

Nordestgaard

Jensen

. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: The Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007; 27: 661–670.

34.

Yusuf

Hawken

Ôunpuu

. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case–control study. Lancet 2004; 364: 937–951.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.15 MB